Real-World MS drug study launches in greece: can kesimpta keep disease in check?
NCT ID NCT06486779
First seen Jan 06, 2026 · Last updated May 14, 2026 · Updated 23 times
Summary
This study looks at how well the drug ofatumumab (Kesimpta®) controls relapsing multiple sclerosis (MS) in 160 people in Greece who are receiving it as part of their normal medical care. Researchers will compare results to a previous clinical trial to see if the drug prevents relapses, brain lesions, and disability worsening. Participants must have started ofatumumab within the last 3 to 6 months and have had MS for less than 5 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS (RMS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGAlexandroupoli, 681 00, Greece
-
Novartis Investigative Site
RECRUITINGAthens, 115 21, Greece
-
Novartis Investigative Site
RECRUITINGAthens, 115 25, Greece
-
Novartis Investigative Site
RECRUITINGAthens, 115 27, Greece
-
Novartis Investigative Site
RECRUITINGAthens, 115 28, Greece
-
Novartis Investigative Site
ACTIVE_NOT_RECRUITINGAthens, 145 61, Greece
-
Novartis Investigative Site
RECRUITINGAthens, 185 47, Greece
-
Novartis Investigative Site
RECRUITINGChaïdári, 124 62, Greece
-
Novartis Investigative Site
RECRUITINGCrete Heraklion, 714 09, Greece
-
Novartis Investigative Site
RECRUITINGIoannina, 455 00, Greece
-
Novartis Investigative Site
RECRUITINGLarissa, 411 10, Greece
-
Novartis Investigative Site
RECRUITINGPátrai, 265 04, Greece
-
Novartis Investigative Site
RECRUITINGThessaloniki, 53246, Greece
-
Novartis Investigative Site
RECRUITINGThessaloniki, GR 54636, Greece
Conditions
Explore the condition pages connected to this study.